Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: A phase IV, randomized, placebo-controlled trial

American Journal of Cardiovascular Drugs

Volumn 13, Issue 2, 2013, Pages 129-140

  Weiss, Robert J ^a   Stapff, Manfred ^b   Lin, Yuhua ^b  

^a Maine Research Associates   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LISINOPRIL; LOSARTAN; NEBIVOLOL; PLACEBO;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BRADYCARDIA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PHASE 4 CLINICAL TRIAL; PLACEBO EFFECT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SYSTOLIC BLOOD PRESSURE; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZOPYRANS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; HUMANS; HYPERTENSION; LISINOPRIL; LOSARTAN; MALE; MIDDLE AGED; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84880669269     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.1007/s40256-013-0010-y     Document Type: Article

References (42)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206-52.
2. Gradman AH, Basile JN, Carter BL, Bakris GL. Combination therapy in hypertension. J Am Soc Hypertens. 2010;4(1):42-50.
3. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122(3):290-300.
4. Munzel T, Gori T. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol. 2009;54(16):1491-9.
5. Weiss RJ, Saunders E, Greathouse M. Efficacy and tolerability of nebivolol in stage I-II hypertension: a pooled analysis of data from three randomized, placebo-controlled monotherapy trials. Clin Ther. 2011;33(9):1150-61.
6. Neutel JM, Smith DH, Gradman AH. Adding nebivolol to ongoing antihypertensive therapy improves blood pressure and response rates in patients with uncontrolled stage I-II hypertension. J Hum Hypertens. 2010;24(1):64-73.
7. Weber MA, Basile J, Stapff M, Khan B, Zhou D. Blood pressure effects of combined beta blocker and angiotensin converting enzyme inhibitor therapy compared with the individual agents: a placebo-controlled study with nebivolol and lisinopril. J Clin Hypertens (Greenwich). 2012;14(9):588-92.
8. Lacourciere Y, Arnott W. Placebo-controlled comparison of the effects of nebivolol and low-dose hydrochlorothiazide as monotherapies and in combination on blood pressure and lipid profile in hypertensive patients. J Hum Hypertens. 1994;8(4):283-8.
9. Lacourciere Y, Lefebvre J, Poirier L, Archambault F, Arnott W. Treatment of ambulatory hypertensives with nebivolol or hydrochlorothiazide alone and in combination. A randomized, double-blind, placebo-controlled, factorial-design trial. Am J Hypertens. 1994;7(2):137-45.
10. Fretheim A, Oxman AD. International variation in prescribing antihypertensive drugs: its extent and possible explanations. BMC Health Serv Res. 2005;5(1):21.
11. Gu Q, Paulose-Ram R, Dillon C, Burt V. Antihypertensive medication use among US adults with hypertension. Circulation. 2006;113(2):213-21.
12. Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007;13(8 Suppl B):9-20.
13. Blumenfeld JD, Sealey JE, Mann SJ, Bragat A, Marion R, Pecker MS, et al. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am J Hypertens. 1999;12(5):451-9.
14. Stanton T, Reid JL. Fixed dose combination therapy in the treatment of hypertension. J Hum Hypertens. 2002;16(2):75-8.
15. MacGregor GA, Markandu ND, Banks RA, Bayliss J, Roulston JE, Jones JC. Captopril in essential hypertension; contrasting effects of adding hydrochlorothiazide or propranolol. Br Med J (Clin Res Ed). 1982;284(6317):693- 6.
16. Wing LM, Chalmers JP, West MJ, Russell AE, Morris MJ, Cain MD, et al. Enalapril and atenolol in essential hypertension: attenuation of hypotensive effects in combination. Clin Exp Hypertens A. 1988;10(1):119-33.
17. Bisognano JD, McLaughlin T, Roberts CS, Tang SS. Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: effectiveness in combination with diuretics or beta-blockers for treating hypertension. Vasc Health Risk Manag. 2007;3(5):579-85.
18. Greathouse M. Nebivolol efficacy and safety in patients with stage I-II hypertension. Clin Cardiol. 2010;33(4):E20-7.
19. Lewin A, Punzi H, Luo X, Stapff M. Nebivolol monotherapy for patients with systolic stage II hypertension: results of a randomized, placebo-controlled trial. Clin Ther. 2013;35(2):142-52.
20. Papademetriou V. Comparison of Nebivolol monotherapy versus Nebivolol in combination with other antihypertensive therapies for the treatment of hypertension. Am J Cardiol. 2009;103(2):273-8.
21. Punzi H, Lewin A, Lukic T, Goodin T, Wei C. Efficacy and safety of nebivolol in Hispanics with stage I-II hypertension: a randomized placebo-controlled trial. Ther Adv Cardiovasc Dis. 2010;4(6):349-57.
22. Saunders E, Smith WB, DeSalvo KB, Sullivan WA. The efficacy and tolerability of nebivolol in hypertensive African American patients. J Clin Hypertens (Greenwich). 2007;9(11):866-75.
23. Weiss RJ, Weber MA, Carr AA, Sullivan WA. A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension. J Clin Hypertens (Greenwich). 2007;9(9):667-76.
24. Brickman AM, Reitz C, Luchsinger JA, Manly JJ, Schupf N, Muraskin J, et al. Long-term blood pressure fluctuation and cerebrovascular disease in an elderly cohort. Arch Neurol. 2010;67(5):564-9.
25. Parati G, Faini A, Valentini M. Blood pressure variability: its measurement and significance in hypertension. Curr Hypertens Rep. 2006;8(3):199-204.
26. Asmar R, Safar M, Queneau P. Evaluation of the placebo effect and reproducibility of blood pressure measurement in hypertension. Am J Hypertens. 2001;14(6 Pt 1):546-52.
27. Bienenfeld L, Frishman W, Glasser SP. The placebo effect in cardiovascular disease. Am Heart J. 1996;132(6):1207-21.
28. Preston RA, Materson BJ, Reda DJ, Williams DW. Placebo-associated blood pressure response and adverse effects in the treatment of hypertension: observations from a Department of Veterans Affairs Cooperative Study. Arch Intern Med. 2000;160(10):1449-54.
29. Enck P, Benedetti F, Schedlowski M. New insights into the placebo and nocebo responses. Neuron. 2008;59(2):195-206.
30. Mutti E, Trazzi S, Omboni S, Parati G, Mancia G. Effect of placebo on 24-h non-invasive ambulatory blood pressure. J Hypertens. 1991;9(4):361-4.
31. Bakris GL, Lindholm LH, Black HR, Krum H, Linas S, Linseman JV, et al. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension. 2010;56(5):824-30.
32. Asmar R, Boutelant S, Chaignon M, Guedon J, Topouchian J, Mallion JM, et al. Repeated measurements of non-invasive ambulatory blood pressure: distinction between reproducibility and the proper effect of placebo. Blood Press Monit. 1996;1(3):283-8.
33. Coats AJ, Conway J, Somers VK, Isea JE, Sleight P. Ambulatory pressure monitoring in the assessment of antihypertensive therapy. Cardiovasc Drugs Ther. 1989;3(Suppl 1):303-11.
34. Dupont AG, Van der Niepen P, Six RO. Placebo does not lower ambulatory blood pressure. Br J Clin Pharmacol. 1987;24(1):106-9.
35. Gould BA, Mann S, Davies AB, Altman DG, Raftery EB. Does placebo lower blood-pressure? Lancet. 1981;2(8260-61):1377-81.
36. Mancia G, Omboni S, Parati G, Ravogli A, Villani A, Zanchetti A. Lack of placebo effect on ambulatory blood pressure. Am J Hypertens. 1995;8(3):311-5.
37. O'Brien E, Cox JP, O'Malley K. Ambulatory blood pressure measurement in the evaluation of blood pressure lowering drugs. J Hypertens. 1989;7(4):243-7.
38. Puig JG, Calvo C, Luurila O, Luurila H, Sulosaari S, Strandberg A, et al. Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study with four ABPM. J Hum Hypertens. 2007;21(12):917-24.
39. Agarwal R, Bills JE, Hecht TJ, Light RP. Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control: a systematic review and meta-analysis. Hypertension. 2011;57(1):29-38.
40. McManus RJ, Mant J, Bray EP, Holder R, Jones MI, Greenfield S, et al. Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial. Lancet. 2010;376(9736):163-72.
41. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303(20):2043-50.
42. Germino FW, Lin Y, Pejovic V, Bowen L. Efficacy and tolerability of nebivolol: does age matter? A retrospective analysis of three randomized, placebo-controlled trials in stage I-II hypertension. Ther Adv Cardiovasc Dis. 2012;6(5):185-99.